Zydus Lifesciences Limited — Important, 03-06-2025: General Updates

Zydus Lifesciences’ subsidiary, Zynext Ventures, acquired a 5.9% stake in US immuno-oncology firm Agenus Inc. for about USD 16 million. Agenus’ lead candidates, Botensilimab and Balstilimab, show strong clinical results across nine cancer types. This strategic move enhances Zydus’ footprint in next-gen cancer immunotherapies and supports global expansion of Agenus’ pipeline. Agenus reported USD 103.46 million revenue in 2024, reflecting solid growth potential in high-demand cancer therapies.